The Effect of Intravenous Immunoglobulin on Serum Components in Patients with Recurrent Miscarriage

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500106801

Enrollment

Unknown

Registered

2025-07-30

Start date

2025-08-01

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RSA

Interventions

RSA-IVIG:None

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1.Diagnosed with recurrent miscarriage and has undergone or plans to undergo a systematic etiological screening for recurrent miscarriage at Sun Yat-sen Memorial Hospital of Sun Yat-sen University; 2.Plans to use intravenous immunoglobulin (IVIG) in the current pregnancy preparation or pregnancy; 3.Has read and signed the informed consent form;

Exclusion criteria

Exclusion criteria: 1.Used intravenous immunoglobulin (IVIG) within the past six months. 2.Recurrent miscarriage etiology screening indicates positive ANA, ANA profile, or blocking antibodies. 3.Pre-pregnancy diabetes.

Design outcomes

Primary

Measure	Time frame
Serological markers;	—

Secondary

Measure	Time frame
Early pregnant outcome;Pregnant outcome;	—

Countries

China

Contacts

Public ContactHu Lihao

SUN YAT-SEN MEMORIAL HOSPITAL

413257688@qq.com+86 136 6029 1372

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026